23:33 , Aug 2, 2019 |  BC Extra  |  Company News

Aug. 2 Company Quick Takes: Daiichi's cancer drug gets U.S. approval, plus BioMarin, Acorda, Stemline and more

FDA approves Daiichi's pexidartinib  FDA approved Turalio pexidartinib from Daiichi Sankyo Co. Ltd. (Tokyo:4568) to treat tenosynovial giant cell tumor. A Daiichi spokesperson told BioCentury the drug has been launched at a wholesale acquisition cost...
23:26 , Jun 21, 2019 |  BC Extra  |  Preclinical News

June 21 Preclinical Quick Takes: AnaptysBio targets PD-1 for immune disease; plus Forty Seven, Homology and moreBy BioCentury Staff

AnaptysBio agonizes PD-1 for inflammatory disease  AnaptysBio Inc. (NASDAQ:ANAB) presented what CEO Hamza Suria called “the first data from anyone on a PD-1 agonist mAb” at the 2019 Federation of Clinical Immunology Societies (FOCiS) meeting...
23:49 , Feb 21, 2019 |  BC Week In Review  |  Clinical News

Partial hold for Phase I of Xencor's blood cancer bispecific

Xencor Inc. (NASDAQ:XNCR) said FDA placed a partial clinical hold on a Phase I trial of XmAb14045 following two patient deaths that were considered possibly related to treatment with the bispecific antibody against CD3 and...
20:01 , Feb 20, 2019 |  BC Extra  |  Clinical News

Partial hold for Phase I of Xencor's blood cancer bispecific

Xencor Inc. (NASDAQ:XNCR) said FDA placed a partial clinical hold on a Phase I trial of XmAb14045 following two patient deaths that were considered possibly related to treatment with the bispecific antibody against CD3 and...
01:22 , Jan 4, 2019 |  BC Week In Review  |  Clinical News

Stemline's Elzonris get FDA nod, first therapy for rare blood disorder

FDA approved Elzonris tagraxofusp-erzs (SL-401) from Stemline Therapeutics Inc. (NASDAQ:STML) to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN) in patients ages two and older, making it the indication's first approved therapy. Stemline CEO Ivan Bergstein...
18:38 , Dec 21, 2018 |  BC Extra  |  Company News

Stemline's Elzonris gets FDA nod, first therapy for rare blood disorder

FDA approved Elzonris tagraxofusp-erzs (SL-401) from Stemline Therapeutics Inc. (NASDAQ:STML) to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN) in patients ages two and older, making it the indication's first approved therapy. Stemline CEO Ivan Bergstein...
05:02 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Souped-up CARs at ASH 2018

Rather than searching for new antigens, makers of the latest generation of CAR therapies are focusing on the CARs themselves by designing more sophisticated methods of targeting multiple antigens, controlling cytotoxicity and enhancing tumor-homing. BioCentury’s...
16:46 , Aug 13, 2018 |  BC Extra  |  Company News

Priority Review for Stemline's blood cancer therapy

Stemline Therapeutics Inc. (NASDAQ:STML) said FDA accepted and granted Priority Review to its BLA for Elzonris tagraxofusp (SL-401) to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare form of acute myelogenous leukemia (AML). Its...
22:39 , Apr 3, 2018 |  BC Extra  |  Company News

Allogene gains Pfizer's off-the-shelf CAR T portfolio, announces $300M series A

Newly launched Allogene Therapeutics Inc. (South San Francisco, Calif.) will assume from Pfizer Inc. (NYSE:PFE) rights to off-the-shelf allogeneic CAR T products discovered by Cellectis S.A. (Euronext:ALCLS; NASDAQ:CLLS). Allogene also unveiled a $300 million series...
20:27 , Feb 23, 2018 |  BC Week In Review  |  Company News

Cellectis granted U.S. patents for CRISPR T cell therapies

The U.S. Patent Office granted Cellectis S.A. (Euronext:ALCLS; NASDAQ:CLLS) two patents covering the use of RNA-guided endonucleases to develop T cell immunotherapies. Both patents claim methods of editing T cells using transient expression of CRISPR/nuclease...